Showing 3851-3860 of 10108 results for "".
- OPTiM Trial for T-VEC in Unresectable Melanomahttps://practicaldermatology.com/news/20120604-optim_trial_for_t-vec_in_unresectable_melanoma/2459791/The OPTiM trial for T-VEC (formerly OncoVEXGM-CSF), an oncolytic HSV1 that selectively replicates in tumors, is now underway, according to a presentation by Kaufman, et al. at ASCO 2012. The randomized phase 3 trial will evaluate the efficacy and safety of talimogene laherparepvec (T-VEC) compared w
- Scleroderma Foundation to Honor Genentech's Dr. Jeffrey Siegel for Scientific Contributionshttps://practicaldermatology.com/news/scleroderma-foundation-to-honor-genentechs-dr-jeffrey-siegel-for-scientific-contributions/2458864/Dr. Jeffrey Siegel, Senior Group Medical Director of Immunology at Genentech, will be honored by the Scleroderma Foundation of Southern California with the Spirit of Leadership Award at their 17th annual “Key to a Cure” gala, which will be held on Saturday, Octobe
- Soligenix's Phase 3 FLASH Study Continues to Demonstrate Positive Benefits of SGX301 in Cutaneous T-Cell Lymphoma Patientshttps://practicaldermatology.com/news/soligenixs-phase-3-flash-study-continues-to-demonstrate-positive-benefits-of-sgx301-in-cutaneous-t-cell-lymphoma-patients/2460576/Continued optional treatment with Soligenix, Inc.’s SGX301 (synthetic hypericin) demonstrates positive benefits in patients with cutaneous T-Cell lymphoma Nearly half of all patients in Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) trial conti
- FDA Grants Soligenix Fast Track Designation for SGX301 for First-Line Treatment of Cutaneous T-Cell Lymphomahttps://practicaldermatology.com/news/fda-grants-soligenix-fast-track-designation-for-sgx301-for-first-line-treatment-of-cutaneous-t-cell-lymphoma/2459030/Soligenix, Inc.’s SGX301 (synthetic hypericin) development program for the first-line treatment of cutaneous T-cell lymphoma (CTCL) received "fast track" designation from the FDA. Fast track is a designation that the FDA reserves for a drug intended to treat a serious or life-thre
- Pulse Biosciences, Inc.’s Nano-Pulse Stimulation Technology Produces Favorable Results for Warts and Allhttps://practicaldermatology.com/news/pulse-biosciences-incs-nano-pulse-stimulation-technology-produces-favorable-results-for-warts-and-all/2460457/Three studies show positive results for Pulse Biosciences, Inc.’s investigational use of Nano-Pulse Stimulation non-thermal energy in nodular basal cell carcinoma (BCC), sebaceous hyperplasia (SH) lesions and cutaneous non-genital warts. In addition, pre-clinical observations of t
- T-VASI and F-VASI Shown Reliable in Nonsegmental Vitiligo Assessmenthttps://practicaldermatology.com/news/t-vasi-and-f-vasi-shown-reliable-nonsegmental-vitiligo-assessment/2468550/New research confirmed that the Total Vitiligo Area Scoring Index (T-VASI) and the Facial VASI (F-VASI) are reliable and valid tools for measuring meaningful improvement in patients with nonsegmental vitiligo. The study, published in JAMA Dermatology, included 164 adult participa
- USPTO Grants Patents to TOOsonix A/S for HIFU Technologies in Dermatologyhttps://practicaldermatology.com/news/uspto-grants-patents-to-toosonix-as-for-hifu-technologies-in-dermatology/2461420/The United States Patent and Trademark Office (USPTO) granted TOOsonix A/S patents regarding its key high-intensity focused ultrasound (HIFU) technologies for dermatology The U.S. patent and already granted patents in Europe and China to complete the first phase of securing intellectual prop
- Hoth Therapeutics, Inc.’s BioLexa in AD: So Far, So Safehttps://practicaldermatology.com/news/hoth-therapeutics-incs-biolexa-in-ad-so-far-so-safe/2460853/Hoth Therapeutics, Inc.’s BioLexa was well tolerated with no serious adverse events and no drug-related treatment-emergent adverse events observed, according to the safety results in Cohort 1 of its first in human clinical trial of the BioLexa platform to treat atopic dermatitis.
- TOOsonix A/S Rolls Out System ONE-M for Aesthetic Treatmentshttps://practicaldermatology.com/news/toosonix-as-rolls-out-system-one-m-for-aesthetic-treatments/2460449/TOOsonix A/S is launching its CE-marked System ONE-M for color-independent tattoo removal, solar lentigines, spider veins, angiomas, telangiectasia and other aesthetic conditions. System ONE-M is a focused ultrasound device operati
- Thumbs Down for Neothetics, Inc.'s LIPO-202; Stock Plummetshttps://practicaldermatology.com/news/thumbs-down-for-neothetics-incs-lipo-202/2458145/Neothetics, Inc.’s LIPO-202 for the reduction of submental subcutaneous fat failed to demonstrate improvement on any efficacy measurements or separation from placebo in a Phase 2 proof-of-concept trial. Neothetics Inc. shares droppe